Clinical Trials
9 trialsNCT01892371 2025-04-06
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02834390 2025-03-05
Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Daiichi Sankyo
Phase 1 Completed
NCT02668653 2024-08-06
QuANTUM-First
Daiichi Sankyo
Phase 3 Completed
NCT01411267 2022-04-04
AC220 for Children With Relapsed/Refractory ALL or AML
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
NCT02039726 2021-02-24
(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
Daiichi Sankyo
Phase 3 Completed
NCT00462761 2020-05-11
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Daiichi Sankyo
Phase 1 Completed
NCT02984995 2020-02-17
Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation
Daiichi Sankyo
Phase 2 Completed
NCT01565668 2019-12-27
Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Daiichi Sankyo
Phase 2 Completed
NCT00989261 2019-12-11
ACE
Daiichi Sankyo
Phase 2 Completed